Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03056872|
Recruitment Status : Recruiting
First Posted : February 17, 2017
Last Update Posted : January 25, 2019
|Condition or disease|
|Alcohol Use Disorder Anxiety Disorder/Anxiety State Stress Disorder Hypothalamic Pituitary Adrenal Drinking to Cope|
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Official Title:||Physiological Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes|
|Actual Study Start Date :||October 5, 2018|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||April 2022|
AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
AnxD+AUD-Cognitive Behavioral Therapy (CBT)
AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
AnxD+AUD- No CBT
AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
- Relapse Status [ Time Frame: 4-month follow-up ]Relapse status will be assessed using a categorical measure of whether someone did vs did not drink (yes vs. no) during the 4 months following treatment discharge.
- Relapse Severity [ Time Frame: 4-month follow-up ]Relapse severity will consist of the number days drinking during the 4 months following treatment discharge.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03056872
|Contact: Justin J Anker, Ph.D.||email@example.com|
|Contact: Nikki Degeneffe, BSfirstname.lastname@example.org|
|United States, Minnesota|
|University of Minnesota Fairview Riverside||Recruiting|
|Minneapolis, Minnesota, United States, 55454|
|Contact: Nikki Degeneffe 612-625-7546 email@example.com|
|Principal Investigator:||Justin Anker, PhD||University of Minnesota - Clinical and Translational Science Institute|